Knopp Biosciences Reports Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
05/17/2021 | 06:01am EDT
Send by mail :
Message :
Dexpramipexole was well tolerated, with 97% of drug-treated patients completing the primary assessment phase
Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma. The data were presented in a virtual poster session at the ATS 2021 International Conference.
The EXHALE trial was a randomized, double-blind, placebo-controlled study of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL. Dexpramipexole study drug at oral doses of 75 mg/day, 150 mg/day, or 300 mg/day was added to standard of care. The primary endpoint was change in AEC from Baseline to Week 12 compared to placeb
Search jobs 16-Dec-2020 First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis
New clinical trial also announced for Fasenra
in eosinophilic gastritis/eosinophilic gastroenteritis
The first patients have been dosed in
Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with polyangiitis (EGPA)
AstraZeneca will also initiate a Phase III trial to investigate the potential of
Fasenra in an additional rare eosinophilic disease: eosinophilic gastritis/eosinophilic gastroenteritis (EG/EGE). This trial extends the
Fasenra clinical programme to nine diseases where eosinophils play an important role, in addition to severe asthma.